Evolent Health (NYSE:EVH - Get Free Report) had its target price boosted by stock analysts at Canaccord Genuity Group from $6.00 to $7.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a "buy" rating on the technology company's stock. Canaccord Genuity Group's target price would suggest a potential upside of 17.75% from the stock's previous close.
Other research analysts have also issued reports about the company. Weiss Ratings raised Evolent Health from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 8th. Citigroup lifted their price objective on shares of Evolent Health from $4.00 to $5.50 and gave the stock a "buy" rating in a research report on Friday, May 15th. Needham & Company LLC upped their price objective on shares of Evolent Health from $4.00 to $5.00 and gave the company a "buy" rating in a report on Thursday, May 7th. Finally, Truist Financial lowered shares of Evolent Health from a "buy" rating to a "hold" rating and set a $7.00 price objective on the stock. in a research report on Tuesday, June 30th. Twelve analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Evolent Health currently has an average rating of "Moderate Buy" and an average price target of $6.15.
Get Our Latest Report on Evolent Health
Evolent Health Trading Up 2.3%
Shares of NYSE:EVH opened at $5.95 on Tuesday. Evolent Health has a 52-week low of $2.10 and a 52-week high of $10.35. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.32 and a current ratio of 1.32. The company has a market capitalization of $668.69 million, a P/E ratio of -1.25 and a beta of 0.76. The company has a 50-day simple moving average of $4.77 and a 200 day simple moving average of $3.73.
Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The technology company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.05) by $0.03. The firm had revenue of $496.25 million for the quarter, compared to the consensus estimate of $534.00 million. Evolent Health had a positive return on equity of 0.36% and a negative net margin of 26.29%.The business's revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.06 earnings per share. Sell-side analysts forecast that Evolent Health will post -0.16 earnings per share for the current year.
Institutional Investors Weigh In On Evolent Health
Institutional investors have recently modified their holdings of the business. Brighton Jones LLC bought a new position in Evolent Health during the fourth quarter worth about $3,927,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Evolent Health by 2.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 128,527 shares of the technology company's stock valued at $1,217,000 after purchasing an additional 3,572 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Evolent Health by 162.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company's stock worth $26,861,000 after purchasing an additional 1,754,520 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Evolent Health during the 1st quarter worth approximately $252,000. Finally, Strs Ohio bought a new position in shares of Evolent Health during the first quarter worth approximately $47,000.
About Evolent Health
(
Get Free Report)
Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.
The company's core offerings include care management solutions, population health analytics and clinical advisory services.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
